MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.
Bhin J, Yemelyanenko J, Chao X, Klarenbeek S, Opdam M, Malka Y, Hoekman L, Kruger D, Bleijerveld O, Brambillasca CS, Sprengers J, Siteur B, Annunziato S, van Haren MJ, Martin NI, van de Ven M, Peters D, Agami R, Linn SC, Boven E, Altelaar M, Jonkers J, Zingg D, Wessels LFA.
Bhin J, et al. Among authors: martin ni.
J Exp Med. 2023 Nov 6;220(11):e20211743. doi: 10.1084/jem.20211743. Epub 2023 Aug 29.
J Exp Med. 2023.
PMID: 37642941
Free PMC article.